Abstract
(Abstracted from Obstet Gynecol 2016;128:81–91) In 2008, the US Food and Drug Administration (FDA) issued the first safety communication regarding serious complications associated with the use of transvaginal mesh for pelvic organ prolapse (POP) repair. Since this first safety communication, there have been increasing reports of debilitating mesh complications such as erosion, chronic pain, and dyspareunia, as well as high recurrence rates.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
